HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

NextEdge Admin

03 Nov 2024

3 min 8 sec

In a significant advancement, MGM Medical College in Indore has introduced CAR T cell therapy for blood cancer treatment, making it one of the first government hospitals in India to offer this cutting-edge therapy. This innovative treatment was recently initiated in the Transfusion Medicine Department and Bone Marrow Transplant Unit for a patient with B-cell acute lymphoblastic leukemia (ALL).

Dr. Sanjay Dixit, Dean of MGM Medical College, explained the process: “The procedure involved collecting white blood cells from the patient, modifying them genetically to target cancer cells, and preparing them for reinfusion after 20 days.” CAR T cell therapy reprograms a patient’s T cells to recognize and attack cancer cells, using chimeric antigen receptors (CARs) to identify specific proteins on malignant cells. Once engineered, the CAR T cells are multiplied and reinfused, where they actively seek and destroy cancer cells within the patient’s body.

While CAR T cell therapy has been widely implemented in countries like the USA, Canada, and the UK, India only recently introduced it in 2021 through a collaboration between IIT Mumbai and Tata Memorial Hospital, receiving commercial approval in 2023 from the Central Drugs Standard Control Organization (CDSCO). Although it costs approximately ₹4 crores in the United States, the therapy is now available at one-tenth of this cost in Central India, greatly enhancing accessibility.

The treatment process begins with apheresis to separate white blood cells, followed by genetic modification of T cells with viral vectors. These CAR T cells are cultivated and reinfused, requiring a hospital stay of one to two weeks for monitoring. CAR T cell therapy has shown success rates of 30-40% in relapsed cases, providing new hope to patients unresponsive to other treatments.

“This pioneering initiative at MY Hospital marks a transformative step in blood cancer care, making advanced therapies accessible to more patients in Central India,” noted Dr. Ashok Yadav, Superintendent and HOD of Transfusion Medicine.